Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics Announces Pricing of Public Offering of Common Stock
BURLINGTON, Mass. , May 21, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock at a price to the public of $9.75 per share. The gross proceeds from this offering are expected to be
View HTML
Toggle Summary Flexion Therapeutics Announces Proposed Public Offering of Common Stock
BURLINGTON, Mass. , May 20, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has commenced an underwritten public offering of $75,000,000 of shares of its common stock. Flexion also expects to grant the underwriters a 30-day option to purchase up to an
View HTML
Toggle Summary Flexion Therapeutics to Present at the RBC Capital Markets 2020 Virtual Global Healthcare Conference
BURLINGTON, Mass. , May 13, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the RBC Capital Markets 2020 Virtual Global Healthcare Conference
View HTML
Toggle Summary Flexion Therapeutics Reports First-Quarter 2020 Financial Results and Recent Business Highlights
Company reported ZILRETTA ®  ( triamcinolone acetonide extended-release injectable suspension) net sales of $20.1 million in first quarter 2020 Flexion implementing broad cost savings initiatives; guiding to total operating expenses in the range of $167 million to $177 million for 2020 Phase 2
View HTML
Toggle Summary Flexion Therapeutics Announces Virtual Poster Presentations for FX201, an Intra-Articular Gene Therapy Candidate for the Treatment of Osteoarthritis, at the American Society of Gene & Cell Therapy Annual Meeting
FX201 preclinical in vivo data in a rodent model of OA showed slowing of disease progression 12 weeks post-surgery, persistence of the vector genome in the joint for at least 92 days with absence of systemic distribution, and a favorable safety profile Productivity, purification yields, and product
View HTML
Toggle Summary Flexion Therapeutics Announces Publication of New Abstracts Accepted at Osteoarthritis Research Society International OARSI 2020
An analysis of prospective radiographic assessments of 305 patients showed no adverse joint effects following treatment with ZILRETTA® Analysis of patient mobility indicated patients treated with ZILRETTA walked more steps per day in concert with pain reduction Survey of 1,000 patients with
View HTML
Toggle Summary Flexion Therapeutics to Report First-Quarter 2020 Financial Results on May 7, 2020
BURLINGTON, Mass. , April 30, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2020 financial results after the close of the U.S. financial markets on Thursday, May 7, 2020 . Flexion’s management will host a conference call at
View HTML
Toggle Summary Flexion Therapeutics Announces Positive Preclinical Data Supporting Development of FX301, a Locally Administered Nav1.7 Inhibitor Product Candidate for Post-Operative Pain
New animal data show FX301 provided sustained, post-operative analgesic effect with no impairment in motor function compared to liposomal bupivacaine and placebo High local concentrations of funapide, the active ingredient in FX301, were measured at the site of administration for the duration of
View HTML
Toggle Summary Flexion Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
BURLINGTON, Mass. , April 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 19 th Annual Needham Virtual Healthcare Conference. The
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , April 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to seven new employees consisting of 9,265 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date
View HTML